Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 10;10(1):99.
doi: 10.3390/vaccines10010099.

Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines

Joanna Szczepanek  1 , Monika Skorupa  1   2 , Agnieszka Goroncy  3 , Joanna Jarkiewicz-Tretyn  4 , Aleksandra Wypych  1   5 , Dorota Sandomierz  4 , Aleksander Jarkiewicz-Tretyn  4   6 , Joanna Dejewska  4 , Karolina Ciechanowska  4 , Krzysztof Pałgan  7 , Paweł Rajewski  8 , Andrzej Tretyn  2
Affiliations

Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines

Joanna Szczepanek et al. Vaccines (Basel). .

Abstract

Background: COVID-19 vaccines induce a differentiated humoral and cellular response, and one of the comparable parameters of the vaccine response is the determination of IgG antibodies.

Materials and methods: Concentrations of IgG anti-SARS-CoV-2 antibodies were analyzed at three time points (at the beginning of May, at the end of June and at the end of September). Serum samples were obtained from 954 employees of the Nicolaus Copernicus University in Toruń (a total of three samples each were obtained from 511 vaccinated participants). IgG antibody concentrations were determined by enzyme immunoassay. The statistical analysis included comparisons between vaccines, between convalescents and COVID-19 non-patients, between individual measurements and included the gender, age and blood groups of participants.

Results: There were significant differences in antibody levels between mRNA and vector vaccines. People vaccinated with mRNA-1273 achieved the highest levels of antibodies, regardless of the time since full vaccination. People vaccinated with ChAdOx1 nCoV-2019 produced several times lower antibody levels compared to the mRNA vaccines, while the antibody levels were more stable. In the case of each of the vaccines, the factor having the strongest impact on the level and stability of the IgG antibody titers was previous SARS-CoV-2 infection. There were no significant correlations with age, gender and blood type.

Summary: mRNA vaccines induce a stronger humoral response of the immune system with the fastest loss of antibodies over time.

Keywords: COVID-19; Janssen/Johnson & Johnson; Moderna; Oxford/AstraZeneca; Pfizer/BioNTech; SARS-CoV-2; antibodies; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interest.

Figures

Scheme 1
Scheme 1
Study scheme of patient cohort. Patient cohort details are listed in a hierarchical manner.
Figure 1
Figure 1
Association plot for the group assignment and the vaccine type.
Figure 2
Figure 2
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for various measurements.
Figure 3
Figure 3
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for various measurements grouped by prior COVID-19 infection.
Figure 4
Figure 4
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for various measurements grouped by vaccine type.
Figure 5
Figure 5
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers depending on prior COVID-19 infection.
Figure 6
Figure 6
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for various vaccine types.
Figure 7
Figure 7
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for prior COVID-19 infection grouped by vaccine type.
Figure 8
Figure 8
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for the vaccine type grouped by prior COVID-19 infection.
Figure 9
Figure 9
Box and whisker plots for the IgG anti-SARS-CoV-2 antibodies in all three measurements for various vaccine types grouped by prior COVID-19 infection.
Figure 10
Figure 10
Error bars for 10% trimmed means for IgG anti-SARS-CoV-2 antibody titers with 95% confidence intervals for prior COVID-19 infection.
Figure 11
Figure 11
Error bars for 10% trimmed means for IgG anti-SARS-CoV-2 antibody titers with 95% confidence intervals for the vaccine type.
Figure 12
Figure 12
Error bars for 10% trimmed means for IgG anti-SARS-CoV-2 antibody titers with 95% confidence intervals for each measurement.
Figure 13
Figure 13
Error bars for 10% trimmed means for IgG anti-SARS-CoV-2 antibody titers with 95% confidence intervals for all three measurements grouped by prior COVID-19 infection.
Figure 14
Figure 14
Error bars for 10% trimmed means for IgG anti-SARS-CoV-2 antibody titers with 95%confidence intervals for all three measurements grouped by vaccine type.
Figure 15
Figure 15
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for various measurements grouped by gender.
Figure 16
Figure 16
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for various measurements grouped by age category.
Figure 17
Figure 17
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers for various measurements grouped by blood type.
Figure 18
Figure 18
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers depending on gender.
Figure 19
Figure 19
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers depending on age category.
Figure 20
Figure 20
Box and whisker plots for the IgG anti-SARS-CoV-2 antibody titers depending on blood type.
See this image and copyright information in PMC

References

    1. Zollner A., Watschinger C., Rossler A., Farcet M.R., Penner A., Bohm V., Kiechl S.J., Stampfel G., Hintenberger R., Tilg H., et al. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine. 2021;70:103539. doi: 10.1016/j.ebiom.2021.103539. - DOI - PMC - PubMed
    1. COVID-19 Vaccination Report. [(accessed on 11 December 2021)]; Available online: https://www.gov.pl/web/szczepimysie/raport-szczepien-przeciwko-covid-19.
    1. Turner J.S., O’Halloran J.A., Kalaidina E., Kim W., Schmitz A.J., Zhou J.Q., Lei T., Thapa M., Chen R.E., Case J.B., et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596:109–113. doi: 10.1038/s41586-021-03738-2. - DOI - PMC - PubMed
    1. Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594–599. doi: 10.1038/s41586-020-2814-7. - DOI - PubMed
    1. Teijaro J.R., Farber D.L. COVID-19 vaccines: Modes of immune activation and future challenges. Nat. Rev. Immunol. 2021;21:195–197. doi: 10.1038/s41577-021-00526-x. - DOI - PMC - PubMed

LinkOut - more resources